North China Pharmaceutical Co Ltd Total Liabilities
North China Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, North China Pharmaceutical Co Ltd (600812) has total liabilities worth CN¥14.52 Billion CNY (≈ $2.12 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check North China Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of North China Pharmaceutical Co Ltd (1993–2025)
Total liabilities of North China Pharmaceutical Co Ltd from 1993 to 2025. This chart illustrates how North China Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 600812 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
North China Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of North China Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Supreme Electronics Co Ltd
TW:8112
|
Taiwan | NT$64.28 Billion |
|
PT Sarana Menara
JK:TOWR
|
Indonesia | Rp57.73 Trillion |
|
VIEL & Cie société anonyme
PA:VIL
|
France | €2.21 Billion |
|
Porch Group Inc
NASDAQ:PRCH
|
USA | $780.27 Million |
|
OCI Co Ltd
KO:010060
|
Korea | ₩3.55 Trillion |
|
Deutsche EuroShop AG
F:DEQ
|
Germany | €2.71 Billion |
|
MBB INDUSTRIES
XETRA:MBB
|
Germany | €421.02 Million |
Liability Composition Analysis (1993–2025)
This chart breaks down North China Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 600812 total asset value.
Liquidity & Leverage Metrics
North China Pharmaceutical Co Ltd Total Liabilities Ratios Explained
North China Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how North China Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for North China Pharmaceutical Co Ltd (1993–2025)
The table below shows the annual total liabilities of North China Pharmaceutical Co Ltd from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥14.51 Billion ≈ $2.12 Billion |
-1.96% |
| 2024-12-31 | CN¥14.80 Billion ≈ $2.17 Billion |
+0.75% |
| 2023-12-31 | CN¥14.69 Billion ≈ $2.15 Billion |
-2.04% |
| 2022-12-31 | CN¥14.99 Billion ≈ $2.19 Billion |
-16.30% |
| 2021-12-31 | CN¥17.91 Billion ≈ $2.62 Billion |
+6.14% |
| 2020-12-31 | CN¥16.88 Billion ≈ $2.47 Billion |
+30.65% |
| 2019-12-31 | CN¥12.92 Billion ≈ $1.89 Billion |
+4.13% |
| 2018-12-31 | CN¥12.40 Billion ≈ $1.82 Billion |
+4.50% |
| 2017-12-31 | CN¥11.87 Billion ≈ $1.74 Billion |
+6.13% |
| 2016-12-31 | CN¥11.18 Billion ≈ $1.64 Billion |
+4.26% |
| 2015-12-31 | CN¥10.73 Billion ≈ $1.57 Billion |
+3.97% |
| 2014-12-31 | CN¥10.32 Billion ≈ $1.51 Billion |
-0.93% |
| 2013-12-31 | CN¥10.41 Billion ≈ $1.52 Billion |
+11.23% |
| 2012-12-31 | CN¥9.36 Billion ≈ $1.37 Billion |
-5.93% |
| 2011-12-31 | CN¥9.95 Billion ≈ $1.46 Billion |
+25.37% |
| 2010-12-31 | CN¥7.94 Billion ≈ $1.16 Billion |
+23.85% |
| 2009-12-31 | CN¥6.41 Billion ≈ $937.99 Million |
+19.43% |
| 2008-12-31 | CN¥5.37 Billion ≈ $785.39 Million |
+2.90% |
| 2007-12-31 | CN¥5.22 Billion ≈ $763.27 Million |
-7.10% |
| 2006-12-31 | CN¥5.61 Billion ≈ $821.62 Million |
+1.22% |
| 2005-12-31 | CN¥5.55 Billion ≈ $811.71 Million |
-5.85% |
| 2004-12-31 | CN¥5.89 Billion ≈ $862.15 Million |
+30.66% |
| 2003-12-31 | CN¥4.51 Billion ≈ $659.85 Million |
+5.08% |
| 2002-12-31 | CN¥4.29 Billion ≈ $627.94 Million |
-7.40% |
| 2001-12-31 | CN¥4.63 Billion ≈ $678.12 Million |
+41.82% |
| 2000-12-31 | CN¥3.27 Billion ≈ $478.15 Million |
+12.65% |
| 1999-12-31 | CN¥2.90 Billion ≈ $424.44 Million |
+44.42% |
| 1998-12-31 | CN¥2.01 Billion ≈ $293.89 Million |
+28.34% |
| 1997-12-31 | CN¥1.56 Billion ≈ $229.00 Million |
+12.93% |
| 1996-12-31 | CN¥1.39 Billion ≈ $202.77 Million |
+34.41% |
| 1995-12-31 | CN¥1.03 Billion ≈ $150.86 Million |
+51.01% |
| 1994-12-31 | CN¥682.69 Million ≈ $99.90 Million |
+63.55% |
| 1993-12-31 | CN¥417.41 Million ≈ $61.08 Million |
-- |
About North China Pharmaceutical Co Ltd
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company primarily offers anti-infective, biotechnology, and cardiovascular cerebrovascular drugs; and immunomodulators, vitamins, and health products. It also provides chemical, biological, agricultural, and biopharmaceuticals and veteri… Read more